DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

“…</p>Conclusion<p>Concomitant epidural anesthesia reduced by 15% the EC₅₀ of predicted Ce_prop for LOC, decreased the consumptions of propofol and remifentanil during maintenance of anesthesia, and fastened recovery from anesthesia.…”

Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

“…The RII indicated a 50% higher risk of death in the lowest income group (RII: 1.50; 95% CI: 1.13–1.99), while the SII revealed an absolute difference of 0.16 deaths per 1,000 individuals (p=0.01).…”

Fig 4 - by Leena Inkilä (20614460)

Composite age-depth model and sediment accumulation rate for BF19 & BF87. by John A. F. Wendt (19976392)

Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

“…These findings were used to guide fabrication of a 50 cm² mirror dynamic window and flexible display. …”

Evaluation of serum creatinine (sCr in A) and plasma NGAL (pNGAL in B) in the first 4 consecutive days after KT in non-DGF patients (n = 36). by Vincenzo Cantaluppi (92814)

Effects of different concentrations of propofol on the survival rate of zebrafish embryos and larvae. by Yali Ge (417371)

Example for a parametrically manipulated baby. by Sarah K. C. Holtfrerich (3353693)

Cation Charge Density and Precatalyst Selection in Group 2-Catalyzed Aminoalkene Hydroamination by Merle Arrowsmith (1660063)

“…Hydroamination afforded a series of five- and six-membered pyrrolidine and piperidine derivatives in near quantitative yields with all precatalysts, apart from the barium species, which were apparently limited to a maximum of two turnovers with even the favorable 1-amino-2,2-diphenyl-4-pentene substrate. …”

Effects of anti-TNF-α treatment on insulin sensitivity in skeletal muscle after FTox-G50 injection. by Aouatef Ait-Lounis (151054)

“…(C) Schematic diagram of decreased glucose uptake in skeletal muscle after FTox-G50 injection; up and down arrows indicate increased and decreased expression, respectively.…”

Fig 5 - by Hyun-Jun Kim (1561153)

Fig 3 - by Hyun-Jun Kim (1561153)

Fig 1 - by Hyun-Jun Kim (1561153)

“…<p>A) Chemical structure of Ni. B) Representative crystal violet assay for C2C12 myoblasts treated with Ni for 48 h (IC₅₀ = 2.11 μM). …”

Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells by Tadeja Kuret (5059433)

“…<div><p>Serum amyloid A (SAA) is a sensitive inflammatory marker rapidly increased in response to infection, injury or trauma during the acute phase. …”

Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”